title: Myeloid growth factors.
authors.affiliation: Duke Comprehensive Cancer Center.
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Crawford
authors.forename: James
authors.initials: J
authors.lastname: Armitage
authors.forename: Lodovico
authors.initials: L
authors.lastname: Balducci
authors.forename: Charles
authors.initials: C
authors.lastname: Bennett
authors.forename: Douglas W
authors.initials: DW
authors.lastname: Blayney
authors.forename: Spero R
authors.initials: SR
authors.lastname: Cataland
authors.forename: David C
authors.initials: DC
authors.lastname: Dale
authors.forename: George D
authors.initials: GD
authors.lastname: Demetri
authors.forename: Harry P
authors.initials: HP
authors.lastname: Erba
authors.forename: James
authors.initials: J
authors.lastname: Foran
authors.forename: Alison G
authors.initials: AG
authors.lastname: Freifeld
authors.forename: Marti
authors.initials: M
authors.lastname: Goemann
authors.forename: Mark L
authors.initials: ML
authors.lastname: Heaney
authors.forename: Sally
authors.initials: S
authors.lastname: Htoy
authors.forename: Susan
authors.initials: S
authors.lastname: Hudock
authors.forename: Dwight D
authors.initials: DD
authors.lastname: Kloth
authors.forename: David J
authors.initials: DJ
authors.lastname: Kuter
authors.forename: Gary H
authors.initials: GH
authors.lastname: Lyman
authors.forename: Laura Boehnke
authors.initials: LB
authors.lastname: Michaud
authors.forename: Sarah C
authors.initials: SC
authors.lastname: Miyata
authors.forename: Martin S
authors.initials: MS
authors.lastname: Tallman
authors.forename: Saroj
authors.initials: S
authors.lastname: Vadhan-Raj
authors.forename: Peter
authors.initials: P
authors.lastname: Westervelt
authors.forename: Michael K
authors.initials: MK
authors.lastname: Wong
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects; D003663:Decision Trees; D004334:Drug Administration Schedule; D005334:Fever / Q000139:chemically induced / Q000188:drug therapy* / Q000517:prevention & control; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D009503:Neutropenia / Q000139:chemically induced / Q000188:drug therapy* / Q000517:prevention & control; D018579:Patient Selection; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D018570:Risk Assessment; D014481:United States
chemical_list: D000970:Antineoplastic Agents; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; C455861:pegfilgrastim; D011092:Polyethylene Glycols; C081222:sargramostim; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D000069585:Filgrastim